SiliconBeat

Shares of Alexza Pharmaceutical were trading down about 40 cents, or 8.5 percent Monday in after-hours trading, after the drug maker released preliminary results of its Phase 2 clinical trial of its drug candidate designed to reduce panic attacks.

The good news: the trial uncovered “”no serious adverse events” for those who were given the
drug after being administered a drug-induced panic attack, according to a release the company
filed with the SEC Monday. The bad news, however, is that there was no difference in its
effect compared with that of a placebo.

The filing, which was made shortly after the markets closed Monday, also announced that Alexza
had completed enrollment for its first Phase 3 clinical trial for its inhalation drug
candidate designed to treat acute agitation in patients with schizophrenia or bipolar
disorder.